Get the Stockscreener App
1.37
0.74%
0.01
After Hours:
1.41
0.04
+2.92%
Metavia Inc stock is traded at $1.37, with a volume of 49,466.
It is up +0.74% in the last 24 hours and down -13.29% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$1.36
Open:
$1.35
24h Volume:
49,466
Relative Volume:
0.71
Market Cap:
$9.03M
Revenue:
Net Income/Loss:
$-13.13M
P/E Ratio:
-0.2276
EPS:
-6.0188
Net Cash Flow:
$-15.15M
1W Performance:
+2.24%
1M Performance:
-13.29%
6M Performance:
-3.52%
1Y Performance:
-88.57%
1-Day Range:
$1.325
$1.44
1-Week Range:
$1.325
$1.5887
52-Week Range:
$0.9661
$14.85
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.37 | 9.03M | 0 | -13.13M | -15.15M | -6.0188 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
MetaVia Inc. (MTVA) Slips 2.53% to $1.54 as Shares Drift Toward Lower SupportBreakout Stock Alerts - siam.in
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
MetaVia Highlights DA-1726 Preclinical Data for Obesity Program - TipRanks
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction - PR Newswire
MetaVia (MTVA) Market: Adds 1.39% to Close at $1.46 in the Current Update; Current Setup: the Supplied Trading Band Runs From $1.39 to $1.53 in the Latest ReadingReversal Setup Alerts - dars.gov.et
MetaVia (MTVA) Market: Adds 1.39% to Close at $1.46 in the Current Update; Current Setup: the Supplied Trading Band Runs From $1.39 to $1.53 in the Latest ReadingPCR Spike - vinanet.vn
MetaVia (MTVA) Market: Adds 1.39% to Close at $1.46 in the Current Update; Current Setup: the Supplied Trading Band Runs From $1.39 to $1.53 in the Latest ReadingFade Trade - dars.gov.et
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
MetaVia Inc. (MTVA) Q2 2026 Earnings: Wider-Than-Expected Loss of $0.90 per Share Highlights Pre-Revenue Profile - vinanet.vn
MetaVia Inc. (MTVA) Q2 2026 Earnings: Wider-Than-Expected Loss of $0.90 per Share Highlights Pre-Revenue ProfileBook Value Growth - dars.gov.et
MetaVia Inc. (MTVA) Holds Gains Near $1.49 as Biotech Stock Tests Key ResistanceMA Crossover - vinanet.vn
MetaVia Inc. (MTVA) Holds Gains Near $1.49 as Biotech Stock Tests Key ResistanceATR Stop - dars.gov.et
MetaVia (MTVA) Stock Forum and Discussion - Moomoo
MetaVia (MTVA) Stock Forum and Discussion - Moomoo
MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 - Yahoo Finance
MetaVia Inc. (MTVA) Holds at $1.44: Tight Trading Range Between $1.37 Support and $1.51 Resistance PersistsNegative Gamma - dars.gov.et
MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target Reaffirmed - TipRanks
MetaVia Inc. (MTVA) Slides 4% to $1.43 as $1.36 Support Comes Under PressureIV Contraction - vinanet.vn
MetaVia Inc. (NASDAQ: MTVA) Share Price, MTVA Stock News, MTVA Share Price & Updates - Kalkine
MetaVia Inc. (NASDAQ: MTVA) Share Price, MTVA Stock News, MTVA Share Price & Updates - kalkine.ca
MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MetaVia’s DA-1726 Reaches Highest Doses in Phase 1 Study Ahead of 2026 Results - The Clinical Trial Vanguard
MetaVia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MetaVia Advances DA-1726 and Vanoglipel in Q2 Update - TipRanks
MetaVia Inc. Q2 2026: Net loss $5.3M, EPS $(0.90) — 10-Q Summary - TradingView
MTVA: Q2 2026 saw clinical progress and a $5.3M net loss, with cash reserves at $12.6M - TradingView
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
MetaVia Inc. (MTVA) Holds Steady at $1.46 as Shares Consolidate Between Key LevelsFear Greed Index - dars.gov.et
MetaVia Inc. (MTVA) Holds Steady at $1.46 as Shares Consolidate Between Key LevelsValue Area High - dars.gov.et
MetaVia Inc expected to post a loss of 82 cents a shareEarnings Preview - TradingView
MetaVia Inc. (MTVA) Slips to $1.42 as Stock Tests Key Support at $1.35Volume Gap - dars.gov.et
MetaVia Inc. (MTVA) Slips to $1.42 as Stock Tests Key Support at $1.35Elliott Wave Count - vinanet.vn
MTVA: Advancing next-gen obesity and MASH therapies with strong clinical data and near-term catalysts - tradingview.com
MetaVia Inc. (MTVA) Slips to $1.40 as Support Holds at $1.33Bullish Percent Index - vinanet.vn
Form S-1 MetaVia Inc For: 29 July By Investing.com - Investing.com Nigeria
Form S-1 MetaVia Inc For: 29 July By Investing.com - Investing.com Canada
MTVA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue Development StageEarnings Power Value - vinanet.vn
MTVA|MetaVia Inc|Price:1.450|Chg%:-0.030 - TradingKey
MetaVia Inc (MTVA) Income Statement - TradingKey
MetaVia Inc (MTVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MetaVia Inc (MTVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
MetaVia Inc (MTVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dong-A ST, Metavia push Vanoglipel to lead MASH, diabetes therapiesCHOSUNBIZ - Chosunbiz
MetaVia Inc (MTVA) Institutional Confidence - TradingKey
MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MetaVia Inc (MTVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MetaVia Inc. (MTVA) Slips 1.99% as Shares Trade Near Key Support LevelsArms Index - dars.gov.et
MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MetaVia Inc (MTVA) Cash Flow - TradingKey
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):